Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test in describe participant population. The main
questions it aims to answer are:
1. evaluate the efficacy and safety of tislelizumab combined with APF sequential surgery or
radical concurrent chemoradiotherapy in the treatment of locally advanced head and neck
tumors.
2. the exploration of efficacy-related immune microenvironment genes Participants will
receive tislelizumab combined with APF sequential surgery or radical concurrent
chemoradiotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School